Rare disease clinical trials present unique challenges for sponsors, particularly when patient populations are small, geographically dispersed, and underserved.
When sponsors lack established connections with patient communities, trial design, recruitment, and retention can suffer. The focus is shifting from sponsor-led assumptions to structured, patient-centric engagement with patient advocacy organizations (PAOs) to ensure ethical trial conduct, meaningful participation, and long-term development success.
Read our case study to explore more about:
- How to build meaningful relationships with rare disease patient advocacy organizations
- How PAO engagement improves trial awareness, recruitment, and retention
- How patient insights can inform protocol design and reduce participation barriers
- How structured, ethical collaboration supports long-term development and patient trust